Articles by Louis Garguilo

61. Quality Adds Empathy To Outsourcing 3/7/2018

    Vinita Kumar, VP of quality at Versartis, talks about how her philosophy on CMO collaboration has been field-tested. “Never does that importance of real collaboration reveal itself more than in hard times for your program when you need it most,” she says.

62. How Some Sponsors Internally Evaluate Their CDMOs 3/7/2018

    A panel of supply chain experts share best practices and perspectives on what parameters to use in evaluating CMOs/CDMOs, how to address low performance partners, and how to meet growing FDA expectations.

63. Virtual And Variable: Two Visions For Biopharma Outsourcing In 2018 12/7/2017

    Deborah Dunsire, CEO of XTuit Pharmaceuticals; and Robert Discordia, executive director, global product development & supply procurement for Bristol-Myers Squibb discuss new approaches to external partnerships in pharma.

64. Two Strategies For Getting Your CMO To Really Listen 10/11/2017

    “When you select a vendor and agree to a contract, your roles are now somewhat reversed. You were the boss before you handed out the contract, but the minute the contract is done, you lose the leverage you had. How can you maintain more control?” Here are two strategies from biotech and pharma executives.

65. Boehringer Ingelheim And The Two Sides Of Biologics Outsourcing 9/28/2017

    Jens Vogel, President & CEO, BI Fremont Inc., can’t help seeing two sides to most everything associated with the development and manufacturing of biologics. For example, he says we are in an era that at the same time can be dubbed “Death of the Blockbuster” and “Return of the Blockbuster.”

66. Rising Out Of Takeda's Reorganization: New Materials & Innovation 8/9/2017

    “You don’t have time to invest in basic research and wait 10 years. You have to go find individuals and companies doing exciting research, engage them, and progress those new technologies through collaborations and funding,” explains Takeda’s Vincent Ling.

67. What Is Supply Chain Capacity In 2017? 6/5/2017

    “Capacity” for outsourcing development and manufacturing has mostly been defined by a strict calculation of how much material a facility (or facilities) can output over a period of time. Executives from companies like MedImmune and Merck tell us why, unfortunately, that definition doesn’t work anymore.

68. Emerging Biopharma & Their CMOs – Crazy Like A Fox 3/8/2017

    Crazy, that is, like a fox. And this sponsor found an equally crafty CDMO willing to join its pursuit in developing a new class of medicines. Today, that sponsor-provider relationship exemplifies a new model of alliance between emerging biopharma and CMOs.

69. Are CMOs Sufficiently Serving Biotechs? 3/8/2017

    In the summer of 2016, Louis Demers brought his outsourcing experience — including at a J&J company and Genentech — to the newly created role of director of development and manufacturing outsourcing at XOMA, a drug discovery and development company with a portfolio of innovative therapeutic antibodies. His mission: Turn this historically self-reliant biotech into a reliable outsourcer.

70. Guidance & Predictions From New Outsourcing Advisory Board Members 3/8/2017

    The following are new leaders on the Outsourced Pharma Editorial Advisory Board, and they’re not hesitant to provide bold analysis on outsourcing drug development and manufacturing.